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low-dose tumor irradiation completely blocks
tumor development
Oana Draghiciu1, Annemarie Boerma1, Baukje Nynke Hoogeboom1, Hans W Nijman2, and Toos Daemen1,*
1Department of Medical Microbiology; Tumor Virology and Cancer Immunotherapy; University of Groningen; University Medical Center Groningen; Groningen, The Netherlands;
2Department of Gynecology; University of Groningen; University Medical Center Groningen; Groningen, The Netherlands
Keywords: cancer vaccine, low-dose local tumor irradiation, sunitinib, Semliki Forest virus, suppressive factors
Abbreviations: CTL, cytotoxic T lymphocyte; FDA, Food and Drug Administration; HPV, human papilloma virus; MDSC, mye-
loid-derived suppressor; rSFV, recombinant Semliki forest virus; STAT3, signal transducer and activator of transcription 3.
The clinical efficacy of therapeutic cancer vaccines remains limited. For effective immunotherapeutic responses in
cancer patients, multimodal approaches capable of both inducing antitumor immune responses and bypassing tumor-
mediated immune escape seem essential. Here, we report on a combination therapy comprising sunitinib (40 mg/kg),
single low-dose (14 Gy) tumor irradiation and immunization with a therapeutic cancer vaccine based on a Semliki
Forest virus vector encoding the oncoproteins E6 and E7 of human papillomavirus (SFVeE6,7). We previously
demonstrated that either low–dose irradiation or sunitinib in single combination with SFVeE6,7 immunizations
enhanced the intratumoral ratio of antitumor effector cells to myeloid-derived suppressor cells (MDSCs). On the basis of
these results we designed a triple treatment combinatorial regimen.
The trimodal sunitinib, low–dose irradiation and SFVeE6,7 immunization therapy resulted in stronger intratumoral
MDSC depletion than sunitinib alone. Concomitantly, the highest levels of intratumoral E7-specific CD8C T cells were
attained after triple treatment. Approximately 75% of these cells were positive for the early activation marker CD69.
The combination of sunitinib, low-dose tumor irradiation and SFVeE6,7 immunization dramatically changed the
intratumoral immune compartment. Whereas control tumors contained 0.02 E7-specific CD8C T cells per MDSC, triple
treatment tumors contained more than 200 E7-specific CD8C T cells per MDSC, a 10,000-fold increased ratio. As a result,
the triple treatment strongly enhanced the immunotherapeutic antitumor effect, blocking tumor development
altogether and leading to 100% tumor-free survival of tumor-bearing mice. This study demonstrates that this
multimodal approach elicits superior antitumor effects and should be considered for clinical applications.
Introduction
Tumor immunotherapy aims at harnessing the antigen-spe-
cific component of the immune system to reject established
tumors. A wide discrepancy is observed between the high efficacy
of tumor immunotherapy in preclinical studies and clinical trials
in which responses are limited.1,2 One of the reasons for this dif-
ference could be that antigen-specific T cells induced by immu-
notherapy insufficiently migrate and accumulate in the tumor.
Several strategies have been employed to counteract this effect.3
We recently demonstrated that a very effective strategy to
enhance intratumoral migration of antigen-specific T cells is
low-dose, local tumor irradiation.4 Enhanced antitumor
responses following low-dose local tumor irradiation were
explained by the upregulation of T cell chemokine receptors,
induction of tumor vasculature normalization and stimulation
of cross priming by stromal cells.5-8 Addition of local tumor
irradiation to tumor immunotherapy has been reported to
enhance both remodeling of tumor vasculature as well as intra-
tumoral migration of immunization-induced antigen-specific T
cells.9 However, local tumor irradiation also seems to induce a
non-selective intra-tumoral migration and accumulation of vari-
ous types of immune cells, as it also enhanced intratumoral
levels of the immunosuppressive myeloid-derived suppressor
cell (MDSC) population.4 MDSCs are a heterogeneous immu-
nosuppressive population of myeloid origin capable of
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antagonizing antitumoral functions of antigen-specific T cells via
various mechanisms.10,11 An attractive drug targeting MDSCs is
the small molecule tyrosine kinase inhibitor sunitinib, due to i)
its lower toxicity as compared to same-class compounds such as
temsirolimus or bevacizumab;12 ii) FDA approval for treatment
of metastatic renal cell carcinoma patients;13 and iii) capacity to
selectively deplete MDSCs14 and block tumor neoangiogene-
sis.15,16 In a murine 4T1 tumor model, sunitinib reduced expan-
sion of monocytic MDSCs via inhibition of signal transducer
and activator of transcription 3 (STAT3), while simultaneously
inducing apoptosis of the granulocytic MDSC subset.17 Recent
studies have demonstrated a potent enhancement of antitumoral,
immunization-induced immune responses and regression of
tumor growth by combination of MDSC depletion strategies
with tumor immunotherapy.18,19
We developed a cancer vaccine against Human Papillomavirus
(HPV)-induced cancer based on a recombinant alphavirus, spe-
cifically the Semliki Forest virus (rSFV). The rSFV replicon par-
ticles encode a fusion protein of HPV type 16 E6 and E7 derived
from HPV type 16 (SFVeE6,7). Optimized prime-boosting
immunization regimens with SFVeE6,7 particles generate high
levels of HPV-specific T cells and eradicate established HPV-
transformed tumors.20 Furthermore, booster responses against
E6E7 are neither affected by vector-specific antibodies nor by
CTL-mediated killing of infected cells.21 Previously, we have
shown that effector CD8C T cells are responsible for the tumor
eradication effect. In this study, we depleted CD8C, CD4C or
both subsets of T cells with monoclonal antibodies in vivo. In the
group of mice receiving SFVeE6,7 immunization alone, all mice
were protected from tumor outgrowth. When CD4C T cells
were depleted, all mice immunized with SFVeE6,7 remained
resistant to tumor outgrowth. In contrast, in the group of mice
depleted of CD8C T cells, all SFVeE6,7 immunized mice devel-
oped tumors within 2 weeks.22
We recently demonstrated that a combination of irradiation
with SFVeE6,7 immunizations strongly increased the number of
intratumoral HPV-specific cytotoxic T lymphocytes (CTLs), but
at the same time the number of intratumoral MDSCs increased.4
Nevertheless, the overall intratumoral ratio of CTLs to MDSCs
increased leading to enhanced antitumor responses. We next
showed that intratumoral MDSCs can be suppressed with suniti-
nib, also resulting in an augmented immunization efficacy of
SFVeE6,7 immunizations.23 The current study aimed to deter-
mine if the efficacy of therapeutic antitumor immunization could
be further enhanced by a rationally designed multi-therapy
regimen consisting of sunitinib to deplete MDSCs followed by
low-dose local tumor irradiation and therapeutic antitumor immu-
nization to augment CTL activation and migration into the tumor.
Results
Effect of sunitinib, low-dose local tumor irradiation and
therapeutic immunization on the levels of intratumoral MDSCs
First, we determined the effect of triple treatment with suniti-
nib, low-dose local tumor irradiation and therapeutic
immunization on MDSC levels in tumors of TC-1 tumor-bear-
ing mice. Recently, we reported on the enhanced effect induced
by the combination of single low-dose 14 Gy local tumor irradia-
tion and SFVeE6,7 immunization in inducing a potent antigen
specific antitumor immune response.4 In another study, we
showed that administration of sunitinib starting day 7 after
tumor inoculation induced a strong intratumoral MDSC deple-
tion.23 Here, sunitinib was administered similarly, for 9 consecu-
tive days starting day 7 post tumor inoculation to deplete
MDSCs. On day 14 post tumor inoculation, a single 14 Gy low
dosage of local tumor irradiation was given to create a favorable
intratumoral environment for migration and accumulation of
immune cells. The rationale behind using local tumor irradiation
was also to more closely mimic the clinical setting where local
tumor irradiation is routinely used to treat cancer. On the same
day, some groups received one SFVeE6,7 immunization dos-
age with 5 £ 106 viral particles. Confirming previous results,
treatment with sunitinib, alone or in combination with thera-
peutic immunization, led to an approximately 5-fold decrease
in intratumoral MDSCs, as compared to the phosphate
buffered saline (PBS)-control group. Immunization alone
decreased the intratumoral levels of MDSCs 2-fold (Fig. 1A).
Single low-dose local tumor irradiation led to a 1.5-fold
enhancement of MDSCs as compared to the PBS-control
group, also in line with earlier observations.4 When low-dose
local tumor irradiation was combined with therapeutic immu-
nization, this MDSC enhancement was not observed. Interest-
ingly, treatment with sunitinib, low-dose local tumor
irradiation and therapeutic immunization induced the most
potent MDSC depletion, as levels of intratumoral MDSCs
were significantly lower when compared with the groups
receiving SFVeE6,7 immunization in combination with local
tumor irradiation or sunitinib (Fig. 1A).
Effect of triple treatment on intratumoral total and antigen-
specific CD8C T-cell levels, activation state and degranulation
Next, we sought to determine the effect of triple treatment
with sunitinib, low-dose local tumor irradiation and therapeutic
immunization on the intratumoral levels of total and antigen-
specific T cells. To this end, we analyzed the activation status of
total and antigen-specific CD8C T cells as defined by upregula-
tion of CD69, the earliest inducible molecule upon T-cell activa-
tion.24 Functionality of total intratumoral CD8C T cells was
also assessed, by measuring their degranulating fraction
(CD8CCD107aCCD107bC).25
Single treatment with sunitinib or 14 Gy local tumor irradia-
tion led to a 2-fold increase of CD8C T cell levels within tumors
when compared to the PBS-control group, whereas a single
SFVeE6,7 immunization did not increase the number of intra-
tumoral CD8C T cells (Fig. 1B). Sunitinib treatment followed
by a single SFVeE6,7 immunization enhanced intratumoral
CD8C T-cell levels 2.5-fold. The combination of low-dose local
tumor irradiation and SFVeE6,7 immunization strongly
increased the number of intratumoral CD8C T cells, 10-fold
higher when compared to the PBS-control. The combination of
sunitinib, low-dose local tumor irradiation and SFVeE6,7
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immunization induced a
similar boost in intratu-
moral CD8C T-cell levels
(Fig. 1B).
When analyzing the
activation status of total
CD8C T cells, we found
that CD8C T cells iso-
lated from tumors of the
PBS-control group were negative for the activation marker
CD69 (Fig. 1C, left panel). From Figure 1B and
Figure 1C, left panel, it can be deduced that after either sunitinib
treatment or local tumor irradiation approximately 5.8% of total
intratumoral CD8C T cells expressed CD69 on their cell surface.
Combined sunitinib treatment and SFVeE6,7 immunization
enhanced levels of intratumoral CD8C T cells expressing CD69
to approximately 18% of the total intratumoral CD8C T-cell
population. This effect was even more pronounced upon com-
bined treatment with local tumor irradiation and SFVeE6,7
Figure 1. Sunitinib com-




elevates total CD8C and
E7-specific T-cell levels
and activity. (A–D) Mice
were inoculated s.c. with
TC-1 tumor cells. Sunitinib
treatment was started day
7 after tumor inoculation
and mice were injected i.p.
daily for a period of 9 con-
secutive days. Tumors of
mice were irradiated locally
(14 Gy) on day 14 after
tumor inoculation. Mice
were then immunized with
5 £ 106 SFVeE6,7 particles
i.m. on day 14. On day 21
tumors (n D 3¡6/group)
were harvested, cells disso-
ciated, stained with fluoro-
phore-conjugated antibod-
ies and analyzed by the
cytofluorimetry. (A) Analy-
sis of myeloid-derived sup-
pressor cells (MDSCs;
CD11bCGr1C). (B) Analysis
of CD8C T cell numbers
and (C) activation (CD69C
CD8C) and degranulation
status (CD107abCCD8C).
(D) E7-specific CD8C T cells
and their activation status.
A non-parametric Kruskal-
Wallis test, followed by a
Dunn’s multiple compari-
sons test was used to
determine statistical differ-
ences between groups.
Depicted are the statistical
differences between the
double- and triple-treat-
ment groups; *P < 0.05,
**P < 0.01, ***P < 0.001.
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immunization, as percentages of CD8C T cells expressing CD69
increased to 48.7% of the total CD8C T cell population. The
highest percentage of total intratumoral CD8C T cells that
expressed CD69 on their cell surface, 64.2% of CD8C T cells,
was observed after combined triple treatment (Fig. 1B and
Fig. 1C, left panel; flow cytometry analysis: Fig. S1). Similar
results were seen in the degranulating fraction of total intratu-
moral CD8C T cells at day 21 post tumor inoculation (Fig. 1C,
right panel).
We also investigated the levels and activation status of E7-
antigen specific CD8C T cells within tumors. In the PBS-control
group very low (<3 £ 105 cells/g tumor) levels of non-activated
E7-antigen specific CD8C T cells were present. As also shown
previously, single treatment or double treatments of sunitinib,
local tumor irradiation and SFVeE6,7 immunization increased
E7-antigen specific T cells and up-regulated CD69 (Fig. 1D).4
Triple treatment with sunitinib, local tumor irradiation and
SFVeE6,7 immunization further enhanced intratumoral E7-anti-
gen specific CD8C T cells significantly compared to the double
treatment regimens and 34-fold compared to the PBS-control
(Fig. 1D, left panel). Furthermore, 75% of these E7-antigen spe-
cific cells expressed CD69 on their cell surface at the time of anal-
ysis (Fig. 1D, right panel).
Strikingly, the combination of sunitinib, local tumor irradia-
tion and SFVeE6,7 immunization induced a dramatic change in
percentages of E7-specific CD8C T cells and MDSCs within
tumors (Fig. 2A). Whereas control tumors contained 0.02
E7-specific CD8C T cells per MDSC, triple treatment tumors
contained more than 200 E7-specific CD8C T cells per MDSC;
a 10,000-fold increased ratio (Fig. 2B). Triple treatment
increased this ratio 83-fold and 378-fold, compared to double
treatments with sunitinib C SFVeE6,7 and irradiation C
SFVeE6,7, respectively. Notably, this triple treatment also
increased the overall CD8C T cell to MDSC ratio approximately
3,300-fold, 280-fold and 225-fold compared to the PBS-control
group and the groups receiving local tumor irradiation and
SFVeE6,7 immunization or sunitinib and SFVeE6,7 immuniza-
tion, respectively (Fig. 2B).
In vivo antitumor response of triple treatment
Optimal therapeutic immunization regimens with SFVeE6,7,
at a dosage of 5 £ 106 particles administered i.m. on days 7, 14,
21 after tumor inoculation lead to complete TC-1 tumor rejec-
tion in all mice.26 In order to evaluate the effects of combined
sunitinib, local tumor irradiation and SFVeE6,7 immunization
on tumor growth, we immunized mice suboptimally by applying
a lower dosage of 1 £ 106 SFVeE6,7 particles i.m. at a very late
starting time-point for this tumor model, i.e., on days 14, 21 and
28 after tumor inoculation. Sunitinib treatment (40 mg/kg body
weight, i.p.) was started on day 7 after tumor inoculation and
low-dose local tumor irradiation was performed on day 14 post
tumor inoculation. Confirming our previous studies, single suni-
tinib or local tumor irradiation treatment did not delay or pro-
mote tumor growth compared to the untreated group24,4 and
mice were sacrificed at similar time points. The suboptimal
SFVeE6,7 immunization alone, resulted in a delay in tumor
growth as compared to the PBS or single treatment groups
(Fig. 3). This delay in tumor growth was even more pronounced
Figure 2. Intratumoral levels and ratios of E7-specific CD8C T cells and MDSCs upon combined triple treatment. On day 7 after tumor inoculation, suniti-
nib treatment was started on day 7 after tumor inoculation and mice were injected daily i.p. for a period of 9 consecutive days. Mouse tumors were
locally irradiated with a 14 Gy irradiation dosage at day 14 post tumor inoculation. Mice were then immunized with 5 £ 106 SFVeE6,7 particles by i.m.
injection on day 14. On day 21 tumors were harvested, cells dissociated, stained with fluorophore-conjugated antibodies and analyzed by the cyto-
fluorimetry. (A) Percentages of E7-antigen specific CD8C T cells (dark gray) and myeloid-derived suppressor cells (MDSCs; light gray) within tumors of
each treatment group (nD 3¡6/group). Pie chart sizes reflect the total combined numbers of E7-antigen specific CD8C T cells and MDSCs present within
tumors of each group at the time of analysis. (B) Table showing the ratios between total CD8C T cells or HPV E7-specific cytotoxic T lymphocytes (CTLs)
and MDSCs within tumors of each treatment group.
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upon combination of local tumor irra-
diation and immunization (Fig. 3). In
the group of mice receiving sunitinib
followed by SFVeE6,7 immunization
82% survived up to day 60 post
tumor inoculation (Figs. 3 and 4).
Strikingly, the combination of
sunitinib, low-dose local tumor irradi-
ation and SFVeE6,7 immunization
abrogated tumor development alto-
gether, thus leading to 100% tumor-
free survival (Figs. 3 and 4). The well-
being of the mice as determined by
weight loss was not affected by the
type of treatment received (Fig. S2).
Discussion
To our knowledge, this is the first
demonstration that multi-therapy
with a tyrosine kinase inhibitor, fol-
lowed by low-dose local tumor irradi-
ation and therapeutic immunization
induces a pronounced depletion of
intratumoral MDSCs while concomi-
tantly elevating levels of intratumoral
antigen-specific, activated CD8C T
cells. Ultimately, this combined treat-
ment led to a striking enhancement in
the ratio of antigen-specific T cells to
MDSCs at the tumor site, an immu-
nologic effect that translated into a
complete inhibition of tumor
development.
Over the course of the last decade,
new paradigms to develop and
improve cancer immunotherapies
have emerged.26 Combinations of can-
cer vaccines with clinically approved
cancer treatments to enhance vaccina-
tion efficacy show promising results.
Preclinical studies indicate enhanced
efficacy of cancer vaccines in tumors
previously depleted of MDSCs.27-29
For this purpose, sunitinib is an attrac-
tive drug due to its selectivity in
depleting MDSCs together with
reports of low clinical toxicity.30-32
Recently, we demonstrated that
sunitinib depletes both intratumoral
and intrasplenic MDSCs and induced
tumor regression in combination with
a cervical cancer therapeutic vac-
cine.23 This combination did not
affect levels of regulatory T cells in
Figure 3. Combined sunitinib, local tumor irradiation and therapeutic vaccination blocks tumor develop-
ment. Mice (n D 6/group) were s.c. inoculated with TC-1 tumor cells., sunitinib treatment was started on
day 7 after tumor inoculation and was administered i.p. daily for a period of 9 consecutive days. Mouse
tumors were locally irradiated with 14 Gy irradiation dosage at day 14 post tumor inoculation. Mice
where then immunized with 106 SFVeE6,7 particles by i.m. injections on days 14, 21 and 28. Tumor
measurements were performed periodically. When the tumor size exceeded 1000 mm3 or when a tumor
protruded through the skin (#) mice were sacrificed for ethical reasons.
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the tumor. However, it should be noted that this tumor contains
very low levels of regulatory T cells and depletion of these cells
with anti-folate receptor 4 antibodies did not enhance immune
responses induced by therapeutic immunization.33
In contrast, Ko JS et al. reported that administration of suniti-
nib to 4T1 tumor-bearing mice lead to depletion of only splenic
MDSCs, whereas intratumoral MDSC levels remained unaf-
fected.17 The authors ascribed this differential effect to pre-con-
ditioning of intratumoral MDSCs with granulocyte macrophage
colony stimulating factor (GM-CSF, also known as CSF2)
secreted within the tumor microenvironment, which subse-
quently inhibited signal transducer and activator of transcription
(STAT3). STAT3 has been shown to be constitutively active in
cervical cancer and directly correlated with over-expression of the
HPV-early proteins E6 and E7.34 Furthermore, in a recent study,
Ren C et al. showed that overexpression of E6 leads to activation
of the IL6/STAT3 pathway. While signaling through the
IL6/STAT3 pathway increased tumor growth, silencing of E6 by
specific shRNA reduced STAT3 activation and tumor growth.35
Additionally, it has been shown that sunitinib inhibited STAT3
in Renca tumor-associated MDSCs and reduced MDSC levels.14
We therefore hypothesize that the mechanism by which intratu-
moral MDSCs are depleted in sunitinib treated E6/E7 expressing
TC-1 tumors is via inhibition of the STAT3 signaling pathway.
Bose et al. recently also reported on studies combining the
tyrosine kinase inhibitors axitinib and sunitinib with OVA-pep-
tide-based vaccines demonstrating reduction of intratumoral
immunosuppressive populations, activation of tumor vascular
endothelial cells and recruitment of vaccine-induced CD8C T
cells to the tumor site.36,37 However, careful scheduling is crucial
when employing combinatorial treatment strategies. This is
underlined by the study of Jaini R et al., wherein concurrent
sunitinib and a-lactalbumin immunization in 4T1 mammary
tumor-bearing mice failed to enhance attenuation of tumor
progression. This result was explained by
sunitinib-mediated inhibition of the
priming phase of immunization. Conse-
quently, authors tested sequential admin-
istration of immunization followed by
sunitinib and found that this consecutive
schedule led to a strong vaccination-
mediated boost in immune responses.38
In our study, administration of sunitinib
was performed prior to immunization.
The rationale for this treatment regimen
was to create a favorable immune envi-
ronment depleted of immune suppres-
sive cells, while simultaneously avoiding
sunitinib-mediated inhibition of the
priming phase of immunization.
We have chosen to combine the anti-
tumoral therapy of sunitinib and thera-
peutic immunization with local tumor
irradiation. We, and others, have shown
localized radiation to induce migration
of total and antigen-specific vaccine-
induced CD8C T cells to the tumor site.4,8 Radiation-induced
upregulation of the chemokine (C-X-C motif) receptor 6
CXCR6 and its ligand CXCL16 –expressed on the surface of
CD8C T cells and tumor cells respectively– may explain the
enhanced migration of T cells.4
Based on the above-mentioned observations the triple treat-
ment regimen was designed. The repeated administration of
sunitinib would be expected to induce and maintain a strong
decrease in the numbers of circulating MDSCs. As irradiation
increases not only the number of intratumoral effector cells but
also the number of MDSCs, we decided to administer sunitinib
prior to low-dose local tumor irradiation and immunization. We
anticipated that administration of sunitinib prior to local tumor
irradiation would therefore decrease MDSC levels before they
had the chance to migrate to tumors. Administration of local
tumor irradiation and therapeutic immunization immediately
after sunitinib treatment would allow for the generation and
tumor infiltration of vaccine-induced antigen-specific antitumor
immune cells in an environment depleted of suppressors and
thus favorable for tumor eradication.
Optimal immunization schemes with SFVeE6,7 alone resulted
in complete tumor eradication. We therefore immunized mice
with a relatively low dosage of 106 SFVeE6,7 particles combined
with a very late starting time-point in order to permit evaluation
of the triple treatment on tumor growth. In previous studies we
have shown that the frequencies of E7-specific CD8C cells in
spleen and blood induced with 105, 106 or 107 SFVeE6,7 particles
do not differ significantly.22,33 It is therefore unlikely that the dos-
age of 106 SFVeE6,7 in the tumor rejection experiments elicited
significantly different numbers of intratumoral CD8C T cells as
compared to the numbers induced with 5 £ 106 SFVeE6,7
(Figs. 1 and 2). As the treatments with sunitinib and local tumor
irradiation were unchanged, the ratio between MDSCs and anti-
gen-specific CD8C T cells will be equal or slightly lower in the
Figure 4. Combination of sunitinib, local tumor irradiation and therapeutic immunization leads to
100% tumor-free survival. Mice (nD6/group) were s.c. inoculated with TC-1 tumor cells., Sunitinib
treatment was started on day 7 after tumor inoculation and was administered, i.p. daily for a period
of 9 consecutive days. Mouse tumors were locally irradiated with 14 Gy irradiation dosage at day 14
post tumor inoculation. Mice where then immunized with 106 SFVeE6,7 particles i.m. on days 14, 21
and 28. Shown are the percentages of survival of tumor-free mice at day 60 post tumor inoculation.
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tumor rejection studies in vivo as compared to the results depicted
in Figure 2. Nevertheless, even at this ratio there is a strong addi-
tive effect in tumor eradication in response to the triple treatment
as compared to the double or single treatments.
The inherent complexity of the multiple routes by which
malignant cells evade immunity dictates the necessity for multi-
modal approaches to aid antitumor immunotherapy achieve its
full therapeutic potential.39,40 The mechanisms of tumor-medi-
ated development of MDSCs and their subsequent capacity to
induce tumor immune escape are present in pre-clinical tumor
models as well as in cancer patients. In this study, we demon-
strated the superior antitumor efficacy of a triple treatment com-
bination of sunitinib, low-dose local tumor irradiation and
therapeutic immunization in a pre-clinical model of HPV-
induced cancer relative to either single or double treatments with
these therapies. Triple treatment resulted in selective MDSC
depletion and simultaneous enhancement of activated vaccine-
induced and antigen-specific T cells, thus leading to a 10,000-
fold increased ratio of vaccine-induced E7-specific T cells to
MDSCs. Our results provide a strong rationale for combining
these treatment modalities to improve cancer immunotherapy.
Materials and Methods
Cell lines
The baby hamster kidney cell line (BHK-21) was obtained in
1996 from the American Type Culture Collection (# CCL¡10).
The TC-1 cell line, generated from C57Bl/6 primary lung epi-
thelial cells with a retroviral vector and expressing human papillo-
mavirus 16 (HPV16) E6E7,41 was obtained in 1998 from Prof.
Dr. Cornelis Melief (Leiden University Medical Center, Leiden,
The Netherlands). Both cell lines were authenticated by mor-
phology and growth characteristics, tested for mycoplasma
and then stored frozen. Upon thawing, both cell lines were cul-
tured for less than 3 months. Additionally, the TC1 cell line was
tested for E7 by Western blot using mouse anti-HPV E7 anti-
body (Zymed Lab, South San Francisco, USA) prior to freezing.
Both cell lines were cultured as described previously.20 Growth
kinetics were recorded and validated at least twice per week.
Mice
Eight to 10 weeks of age specified pathogen-free female
C57BL/6 mice were used (Harlan CPB). The mice were kept
according to institute guidelines and all experiments were
approved by the local Animal Experimentation Ethical
Committee.
Production, purification and titer determination
of SFVeE6,7 particles
Production, purification and titering of SFVeE6,7 particles
were performed as described previously.42 In brief, SFVeE6,7
particles were produced by co-electroporating BHK-21 cells with
an RNA that encodes for the SFV replicase and transgene (the
E6E7 fusion protein), together with a helper RNA that encodes
for the structural proteins of SFV. The produced recombinant
SFV replicon particles were purified on a discontinuous sucrose
density gradient and titrated on BHK-21 cells using a polyclonal
rabbit anti-replicase (nsP3) antibody [gift from Dr. T. Ahola
(Biocentre Viikki, Helsinki, Finland)].
Tumor inoculation, local low-dose tumor irradiation and
SFVeE6,7 immunizations
Mice were inoculated s.c in the neck with 2 £ 104 TC-1 cells
suspended in 0.2 mL Hank’s Balanced Salt Solution (Invitro-
gen). Due to minor variations in tumor growth, at the start of
the treatments mice were divided into groups so that each group
had mice with equal tumor size variations. Sunitinib at 40 mg/kg
body weight was administered i.p. for 9 consecutive days, starting
on day 7 after tumor inoculation.17 Some groups received a sin-
gle 14 Gy local tumor irradiation dosage on day 14 post tumor
inoculation, at a delivery rate of 1.64 Gy/min, using X-RAD 320
Biological Irradiator (Precision X-Ray). Some of the groups were
immunized i.m. on day 14 post tumor inoculation, with a dosage
of 5 £ 106 SFVeE6,7 particles. Tumor volumes were assessed
with calipers and calculated using the formula: volume D [length
£ (width)2]£ 0.7854 for cylindrical tumors or volumeD (diam-
eter)3 £ 0.5236 for spherical tumors. Mice were sacrificed
according to the guidelines of the local ethical committee, if
tumors protruded through the skin, when tumor size exceeded
1000 mm3 or at the end of experiments.
Tumor digestion and cell isolation procedures
On day 21 post tumor inoculation, tumor-bearing mice were
sacrificed, tumors were isolated, weighed, minced into small
pieces and re-suspended in a 37C pre-warmed digestion
medium composed of 1 mg/mL Collagenase A (Roche) in
WiIliam’s E medium (Gibco). The gentleMACSTM Dissociator
(Miltenyi Biotec) was used to homogenize tumors, according to
the manufacturer’s protocol. Homogenized tumors were then
incubated for 30 min at 37C on a shaker (120 rpm). The
homogenization and incubation procedures were repeated once
more and then cells were filtered through a 70 mm Falcon cell
strainer (BD Bioscience). Sterile lysis buffer [(150 mM NH4Cl,
10 mM KHCO3, 0.1 mM Na2-EDTA pH D 7.2–7.4), in a vol-
ume of 5 mL per sample] was used to lyse erythrocytes for 5 min
at room temperature. 15 mL Iscove’s modified Dulbecco’s
medium (IMDM) per sample was used to stop the lysis reaction.
Cell suspensions were then centrifuged, and the supernatant was
discarded and cells resuspended in IMDM with 5% FCS.
Flow cytometry cell staining and analysis
To detect and characterize tumor-infiltrating monocytes and
MDSCs, dissociated tumor cells were stained with PE-Cy7-conju-
gated anti-CD11b and FITC-conjugated anti-Gr1 antibodies. For
CD8C T cell degranulation and activation staining, tumor-associ-
ated cells were cultured in the presence of anti-CD28 antibody
(clone: PV-1, Bioceros BV, Utrecht, The Netherlands) and
eFluorAlexa660-conjugated CD107a (clone: eBio1D4B;) and
CD107b (clone: eBioABL-93) at 37C with 5% CO2. One hour
after culture, 1 mg/mL brefeldin A was added and the cultures
were further incubated for 4 h. Cells were then harvested, washed
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and stained with PE-Cy7-conjugated anti-CD8a and FITC-conju-
gated anti-CD69. For E7-antigen specific CD8C T-cell activation,
cells were stained with PE-conjugated H2-Db RAHYNIVTF tet-
ramers (specific for the antigenic epitope HPV16 E749-57 peptide
RAHYNIVTF) followed by PE-Cy7-conjugated anti-CD8a anti-
body (activated E7-antigen specific CD8C T cells). All antibodies
not otherwise indicated were purchased from eBioscience (San
Diego, CA, USA). Cells were then washed twice in FACS buffer
(PBS containing 0.5% bovine serum albumin) and analyzed by
cytofluorimetry using an LSR-II (BD Biosciences) flow cytometer.
Dead cells were excluded by 4, 6-diamino-2-phenylindole (DAPI)
staining.
Statistical analysis
Data are presented as the mean § standard deviation (SD)
and are representative of at least 2 independent experiments,
with 3–6 mice per group. A non-parametric Kruskal-Wallis test,
followed by a Dunn’s multiple comparisons test was used to
determine statistical differences between groups; P-values of 0.05
or lower were considered significant. GraphPad Prism software,
version 5.0.0.288 (GraphPad software) was used for all statistical
analyses.
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